Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

@article{Kaminski1996Iodine131antiB1RF,
  title={Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.},
  author={M. Kaminski and K. Zasadny and I. R. Francis and M. Fenner and C. Ross and A. Milik and J. Estes and M. Tuck and D. Regan and S. Fisher and S. Glenn and R. Wahl},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 7},
  pages={
          1974-81
        }
}
  • M. Kaminski, K. Zasadny, +9 authors R. Wahl
  • Published 1996
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS Patients were first given tracelabeled doses… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the… Expand
    ConditionsFollicular Lymphoma
    InterventionDrug